Industry landscapes
The companies, capital and talent shaping healthtech in Israel. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
41 of 1,128 tracked companies have open roles.
336 of 1,128 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 601 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 16.0% of disclosed capital, while 70.2% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $307.28M | 81 | 52 |
| 2017 | $655.96M | 65 | 47 |
| 2018 | $526.29M | 69 | 63 |
| 2019 | $556.11M | 52 | 57 |
| 2020 | $1.47B | 84 | 68 |
| 2021 | $756.23M | 38 | 60 |
| 2022 | $993.46M | 32 | 46 |
| 2023 | $522.36M | 20 | 33 |
| 2024 | $715.25M | 11 | 33 |
| 2025 | $485.52M | 2 | 20 |
Share of all disclosed company funding.
699 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by .
Backed by Europa and Junson Capital and others.
Backed by .
Backed by .
Backed by Brainsway.
Backed by .
Backed by Boston Scientific.
Backed by Fidelity Investments and Nexus NeuroTech Ventures and others.
Backed by Koch Disruptive Technologies.
Backed by Elbit Imaging and York Capital Management and others.
Backed by Eclipse and Adani Group and others.
Backed by Battery Ventures and Bessemer Venture Partners and others.
Backed by Koch Disruptive Technologies and Battery Ventures and others.
Backed by Novo Holdings and Viking Global Investors and others.
Backed by Horizons Ventures and Shavit Capital and others.
Backed by CPMG and H.I.G. Capital and others.
No reviewed exact national-ID connector has yet been qualified for Israel; this is a checked implementation boundary, not evidence that filings are absent.
How the Israel companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
7 of the 1,128 companies on this page carry a measured traffic record (0.6%); these are the largest of those, by monthly visits. The median among them is 312,843 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| MyHeritagemyheritage.com | 10,985,503 | 70 | 66.2% |
| Maccabi Health Servicesmaccabi4u.co.il | 4,480,082 | 58 | 72.6% |
| Meuhedetmeuhedet.co.il | 1,046,313 | 50 | 63.1% |
| Infomed Digital Healthinfomed.co.il | 312,843 | 54 | 71.6% |
| Woojer- Born to Feelwoojer.com | 126,812 | 36 | 71.9% |
| Camonicamoni.co.il | 101,211 | 36 | 88.5% |
| remotEMDRremotemdr.com | 89,574 | 26 | 16.6% |
Visits and authority are third-party web estimates, not company-reported figures.
98 of these companies (8.7%) publish at least one Android app — 148 apps in all, carrying 18.4M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Medisafe Pill & Med ReminderMedisafe | 6.3M | 4.5 | Health & Fitness |
| OvuView: Ovulation & FertilityTempdrop | 3.1M | 3.6 | Health & Fitness |
| מכבי שירותי בריאותMaccabi Health Services | 2.1M | 2.8 | Medical |
| Walabot DIYWalabot | 1.4M | 4.2 | Productivity |
| WatchPATItamar Medical | 846.9K | 4.7 | Health & Fitness |
| Sound Sleeper Baby White NoiseSound Sleeper | 715.6K | 4.6 | Parenting |
| מאוחדתMeuhedet | 630.6K | 3.3 | Medical |
| מכבי upappMaccabi Health Services | 521.9K | 4.6 | Health & Fitness |
| Reimagine: Scan & Enhance PicsMyHeritage | 251.4K | 4.2 | Photography |
| מעקב הריון ולידה - פורטיForty | 244.9K | 4.5 | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 72 | 12.6M | Medisafe Pill & Med Reminder 6.3M | |
| Wearable Technology | 51 | 4.9M | OvuView: Ovulation & Fertility 3.1M | |
| Healthcare Booking Platforms | 21 | 4.4M | מכבי שירותי בריאות 2.1M | |
| Assistive Tech | 8 | 1.6M | Walabot DIY 1.4M | |
| Fitness & Wellness Tech | 11 | 973.6K | Sound Sleeper Baby White Noise 715.6K | |
| Cardiac And Vascular Disorders | 19 | 877K | WatchPAT 846.9K | |
| Healthcare It | 73 | 597.8K | TytoCare 202.8K | |
| Medical Devices | 2 | 106.6K | איפה דפי? - מיפוי דפיברילטורים 106.6K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 135 of 148 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
32 companies hiring · $7.86B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated.
Spanish frozen bakery business Monbake Group has struck a deal to acquire local foodservice supplier Triticum.
IceCure Medical Ltd. (Nasdaq: ICCM) (...) announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent fees and other offering expenses.
Cancer diagnostics specialist Guardant Health has completed its $149m acquisition of health technology company, MetaSight Diagnostics, as the company gears up for strong year‑on‑year (YoY) revenue growth in 2026.
Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ Airway Clearance System, announced it has closed an oversubscribed $5 million funding round to accelerate commercial expansion and clinical adoption across the U.S.
OSSIO has closed an initial $40 million senior credit facility, with an additional $10 million available to support future growth, according to Horizon Technology Finance Corporation and Monroe Capital.
The gross proceeds to the Company from the offering are expected to be approximately $4.75 million , before deducting placement agent commissions and other offering expenses.
Haynes Boone represented Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company pioneering oral drug delivery solutions, in its strategic transaction with Lifeward Ltd., a revenue-generating medical robotics company.
Biobeat Technologies, Ltd., developer of the first FDA-cleared, 24-hour ambulatory blood pressure monitoring (ABPM) system that is a patch-worn, cuff-less solution for diagnosis and treatment of hypertension, announced today the closing of a $50 million Series B equity financing. The financing was led by new investors Ally Bridge Group, OrbiMed Advisors and Elevage Medical and included participation from a strategic investor.
Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share.
Top 10 categories among 263 recorded events in the 24-month window.
3 companies with recorded IPO activity
IPO · NYSE American5 reports
IPO · NASDAQ1 reports
IPO1 reports
12 tracked people moves
Appointment Senior Vice President of National Security
Resignation Previously Chief Financial Officer
Resignation Previously Chief Financial Officer
Appointment Chief Financial Officer
Appointment Chairman of the Board of Directors
Resignation
Appointment Chief Executive Officer
Appointment Chairman of the Board
Products, platforms and features in the recorded window
Creator marketing platform
Automation framework
Assessment Tool
3 recorded customer wins
Customer: renovateOphthalmic diagnostics
Customer: LifewardPharmaceuticals
Customer: U.S. General Services AdministrationGovernment services
8 recorded events
approved to adopt SARBritish Columbia Securities Commission
approved for domestic useIsraeli MoH
approved for procurement and operational use by ClalitMedical Equipment Committee of Clalit Health Services
revoked billing privilegesCMS
1 tracked suits
real estate transaction disputeCivil · Settled
Reported company results in the recorded window.
Median across 28 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| medtronic→CathWorks ↗ | Completed | 2026-04-20 | $585.0M |
| Monbake Group→Triticum Medical ↗ | Announced | 2026-04-15 | Not stated in snapshot |
| Alpha Omega→macro solutions | Completed | 2026-03-09 | Not stated in snapshot |
| Alpha Omega→SeKON LLC | Completed | 2026-03-09 | Not stated in snapshot |
| guardant health→MetaSight Diagnostics ↗ | Completed | 2026-02-23 | $149.0M |
| Oramed→Lifeward | Announced | 2026-01-13 | $18.0M |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
Recorded hiring and workforce signals from the available source snapshot.
No repeated job title is supported by this snapshot.
0 tracked postings mention remote work.
| Company | Open roles |
|---|---|
| Lumenis ↗ | 9 |
| Insightec ↗ | 3 |
| Alpha Omega ↗ | 3 |
| HD-MAX ↗ | 2 |
| Microbot Medical ↗ | 2 |
| Neurolief ↗ | 2 |
| IMPLANET ↗ | 2 |
| Commwell ↗ | 2 |
| Company | Employees |
|---|---|
| Novocure ↗ | 1,320 |
| Sisram Medical ↗ | 1,102 |
| SHL Telemedicine ↗ | 402 |
| Vayyar ↗ | 330 |
| Nanox ↗ | 180 |
| Sight Diagnostics ↗ | 169 |
| Insightec ↗ | 144 |
| TailorMed ↗ | 136 |
912 founders and chief executives across 625 companies.
Current CEO of Insightec
Founder Tumor Treating Fields & Novocure.
Ex-Intel, Envara. Ben-Gurion University MSc
Ex-MDG Medical, Be Connected, Applied Materials, Orbot Instruments. Ben-Gurion University of the Negev BSc 1986
8400, IATI, ex-ISL. Technion Israel Institute of Technology BA 2004, MSc 2006, Weizmann Institute of Science PhD 2010
Ex-Ph.D. in Biomedical Engineering Tel-Aviv University
Founder Augmedics, ex-Volume Elements. University of Cambridge MSc 2008, University of Oxford PhD 2011
Founder DisruptionLabs, Getaround.com ex-Better Place. Open University of Israel BA 2000, Tel Aviv University MA 2006
Founder Ossio, ex-IDF Institute for Military Physiology. Columbia University 2004, Technion - Israel Institute of Technology 2006
Ibex Medical Analytics, ex-Comet, ex-Kamet Ventures, Vrije Universiteit Amsterdam, 2011
Bluewind Medical, ex-Direct Flow Medical, ex-White Pine Medical, Bowling Green State University, 1978
Ex-Israel Defense Forces
248 profiles with education records.
10 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
337,305 articles in the measured 12-month window.
Healthtech coverage across Israel · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 36,770 |
| 2021Q3 | 26,280 |
| 2021Q4 | 23,153 |
| 2022Q1 | 23,932 |
| 2022Q2 | 22,304 |
| 2022Q3 | 22,072 |
| 2022Q4 | 24,103 |
| 2023Q1 | 27,453 |
| 2023Q2 | 26,300 |
| 2023Q3 | 25,778 |
| 2023Q4 | 155,766 |
| 2024Q1 | 89,717 |
| 2024Q2 | 94,385 |
| 2024Q3 | 75,241 |
| 2024Q4 | 87,364 |
| 2025Q1 | 74,512 |
| 2025Q2 | 82,940 |
| 2025Q3 | 76,469 |
| 2025Q4 | 45,692 |
| 2026Q1 | 104,779 |
Article volume measures coverage, not market sales.
491 recorded company events across 69 companies; percentages use that event total.
Healthtech coverage across Israel · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Healthtech coverage across Israel
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| diplomatic strategies | 5,878 | 2,757 | 113% |
| national security strategy | 5,781 | 1,415 | 309% |
| foreign policy analysis | 5,329 | 2,315 | 130% |
| multilateral diplomacy | 4,355 | 1,702 | 156% |
| geopolitical alliances | 4,344 | 2,311 | 88% |
| diplomatic engagements | 3,315 | 1,224 | 171% |
| nuclear proliferation | 3,275 | 608 | 439% |
| oil price volatility | 2,796 | 1,341 | 109% |
| humanitarian corridors | 1,918 | 1,327 | 45% |
| diplomatic protocol | 1,884 | 783 | 141% |
| ceasefire violations | 1,904 | 3,733 | -49% |
| hostage negotiations | 1,019 | 2,618 | -61% |
| school bombings | 1,137 | 1,812 | -37% |
| campus police | 283 | 1,391 | -80% |
| campus safety | 297 | 1,363 | -78% |
Healthtech coverage across Israel
aerial bombardments, accidental bombings, diplomatic strategies
80.9% critical · 9.4% positivehigher education funding, school funding battles, currency intervention policies
66.8% critical · 26.8% positiveearnings report, oil price volatility, quarterly financials
44.8% critical · 38.9% positiveHealthtech coverage across Israel. Topic labels describe recorded classifications and can include broad context.
53,214 papers in the recorded worldwide scope.
Tone counts: 46,301 positive · 2,052 neutral · 4,861 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Deep Learning for Health Informatics
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0119.0% of this theme group
Examines factors and methods for building resilient health care systems and administrations.
Health informatics (400) · Health administration (281) · Nursing research (250) · Public health (273)
Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience
Health systems resilience in practice: a scoping review to identify strategies for building resilience
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Common problems researchers identify · 0218.9% of this theme group
Highlights difficulties in multi‑target discovery, repurposing, and regulatory pathways for new therapeutics.
Drug discovery (321) · Drug (197) · Drug development (103) · Disease (155)
A perspective on multi‐target drug discovery and design for complex diseases
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
| Year | Share index |
|---|---|
| 2022 | 157.3 |
| 2023 | 161.8 |
| 2024 | 169.7 |
| 2025 | 211.5 |
Common problems researchers identify · 0315.9% of this theme group
Analyzes obstacles to adopting eHealth tools for universal coverage and behavior change among vulnerable groups.
Digital health (627) · Health care (357) · Digital transformation (69) · eHealth (97)
Technology and Universal Health Coverage: Examining the role of digital health
Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Rev
| Year | Share index |
|---|---|
| 2022 | 538.7 |
| 2023 | 553.0 |
| 2024 | 540.4 |
| 2025 | 843.9 |
Common problems researchers identify · 0414.7% of this theme group
Discusses practical and methodological challenges of delivering remote care and rehabilitation services.
Telemedicine (604) · Telehealth (394) · Health care (334) · Telerehabilitation (53)
Opportunities and challenges for telehealth within, and beyond, a pandemic
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 542.2 |
| 2023 | 554.7 |
| 2024 | 541.1 |
| 2025 | 844.0 |
Common problems researchers identify · 0511.7% of this theme group
Reviews limitations in molecular diagnostics, biomarker validation, and resistance mechanisms for personalized cancer care.
Precision medicine (480) · Personalized medicine (238) · Disease (116) · Precision oncology (28)
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Personalizing Oncology: Perspectives and Prospects
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Common problems researchers identify · 0610.9% of this theme group
Explores risk analysis, energy sourcing, and regulatory gaps for wearable and moderate‑risk equipment.
Medical device (221) · Wearable computer (50) · Medical equipment (27) · Risk analysis (34)
Energy sources and their development for application in medical devices
Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices
| Year | Share index |
|---|---|
| 2022 | 40.4 |
| 2023 | 42.2 |
| 2024 | 43.7 |
| 2025 | 72.1 |
Common problems researchers identify · 078.8% of this theme group
Investigates how COVID‑19 spikes affected telemedicine usage, evaluation, and provider‑patient experiences.
Pandemic (394) · Coronavirus disease 2019 (274) · 2019-20 coronavirus outbreak (69) · Telemedicine (258)
Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study
Telemedicine Evaluations in Neuro-Ophthalmology During the COVID-19 Pandemic: Patient and Physician Surveys
| Year | Share index |
|---|---|
| 2022 | 655.3 |
| 2023 | 440.6 |
| 2024 | 327.7 |
| 2025 | 212.1 |
Cautions · 0119.8% of this theme group
Calls for careful assessment of effectiveness, satisfaction, and safety when using remote care for chronic conditions.
Telemedicine (762) · Telehealth (476) · Telerehabilitation (118) · Health care (319)
The Role of Telemedicine in Improving Healthcare Outcome: A Review
Assessing the Efficiency and Patient Satisfaction of Telemedicine in Managing Chronic Health Conditions
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Cautions · 0219.8% of this theme group
Warns of technical, quality, and equity challenges in deploying informatics and device solutions across diverse settings.
Health informatics (239) · Health administration (157) · Nursing research (113) · Medical device (92)
Challenges of using e-health technologies to support clinical care in rural Africa: a longitudinal mixed methods study exploring primary hea
Development and analysis of quality assessment tools for different types of patient information – websites, decision aids, question prompt l
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Cautions · 0315.3% of this theme group
Notes difficulties in translating biomarkers and predictive models into reliable drug development pipelines.
Drug discovery (202) · Drug (160) · Pharmacogenomics (109) · Pharmacogenetics (64)
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologic
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 158.9 |
| 2024 | 165.9 |
| 2025 | 206.7 |
Cautions · 0414.7% of this theme group
Highlights gaps in evidence, user experience, and scalability for digital psychological and preventive programs.
Digital health (480) · Psychological intervention (265) · Mental health (159) · Health care (262)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digital Health Interventions for Promoting Healthy Aging: A Systematic Review of Adoption Patterns, Efficacy, and User Experience
| Year | Share index |
|---|---|
| 2022 | 790.2 |
| 2023 | 807.5 |
| 2024 | 810.9 |
| 2025 | 1159.7 |
Cautions · 0511.2% of this theme group
Examines clinician perspectives and barriers to sustained telemedicine use during and after the pandemic.
Pandemic (431) · Coronavirus disease 2019 (360) · Telemedicine (348) · 2019-20 coronavirus outbreak (77)
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
Exploring Ophthalmologists’ Adoption of Telemedicine during the COVID-19 Pandemic: A Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 544.1 |
| 2023 | 376.7 |
| 2024 | 243.3 |
| 2025 | 191.2 |
Cautions · 0610.3% of this theme group
Discusses limited awareness, understanding, and practical uptake of personalized cancer therapies worldwide.
Precision medicine (249) · Personalized medicine (164) · Cancer (103) · Oncology (57)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Sur
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
| Year | Share index |
|---|---|
| 2022 | 767.8 |
| 2023 | 1043.6 |
| 2024 | 798.0 |
| 2025 | 771.4 |
Cautions · 078.8% of this theme group
Raises ethical, interpretability, and reliability issues surrounding artificial‑intelligence applications in health care.
Applications of artificial intelligence (102) · Transformative learning (77) · Health care (188) · Precision medicine (102)
Artificial intelligence in healthcare: revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous di
Artificial Intelligence in Medicine: Transforming Diagnosis, Treatment, and Healthcare Delivery
| Year | Share index |
|---|---|
| 2022 | 534.7 |
| 2023 | 549.6 |
| 2024 | 538.1 |
| 2025 | 839.2 |
Opportunities · 0118.0% of this theme group
Identifies emerging models and human‑centered designs that improve clinical adoption of digital tools.
Digital health (282) · Health care (348) · Health informatics (142) · Psychological intervention (156)
Development of an Evidence-Based Conceptual Model of the Health Care Sector Under Digital Transformation: Integrative Review
HCI-modelling for improving the clinical usability of digital health technologies
| Year | Share index |
|---|---|
| 2022 | 541.3 |
| 2023 | 554.6 |
| 2024 | 543.2 |
| 2025 | 853.3 |
Opportunities · 0216.5% of this theme group
Highlights computational screening and docking methods accelerating identification of novel therapeutic candidates.
Drug discovery (281) · In silico (99) · Drug (155) · Docking (85)
Exploring Cimetidine\nas a Potential Therapeutic Attenuator\nagainst Amyloid Formation in Parkinson’s Disease: Spectroscopic\nand Microscopi
Design, Synthesis,\nand Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑<i>b</i>]pyridine-3-carboxamides as New Selective, Potent,
| Year | Share index |
|---|---|
| 2022 | 167.5 |
| 2023 | 172.4 |
| 2024 | 180.4 |
| 2025 | 218.9 |
Opportunities · 0313.8% of this theme group
Shows how molecular docking and chemical‑space exploration enhance targeted drug design processes.
Drug discovery (536) · Computational biology (222) · Drug (224) · Chemical space (66)
Assessing molecular docking tools: understanding drug discovery and design
Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 281.3 |
| 2023 | 298.1 |
| 2024 | 330.7 |
| 2025 | 367.6 |
Opportunities · 0413.7% of this theme group
Explores tele‑based physical therapy and palliative care models expanding access for seniors and complex patients.
Telemedicine (475) · Telehealth (353) · Telerehabilitation (87) · Physical therapy (75)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Telehealth for the study of palliative care communication: opportunities, methodological challenges, and recommendations
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Opportunities · 0512.7% of this theme group
Describes advances in tailoring treatments for heterogeneous diseases using genomic and deep‑learning approaches.
Precision medicine (283) · Personalized medicine (216) · Disease (142) · Pharmacogenomics (61)
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Deep Learning for Precision Medicine: Advancing Personalized Treatment Plans in Oncology
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Opportunities · 0612.7% of this theme group
Details how connected devices enable continuous health tracking and care delivery in underserved areas.
Wearable computer (117) · Medical device (84) · Remote patient monitoring (76) · Internet of Things (49)
Wearable technology. Health-care solutions for a growing global population.
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.5 |
| 2023 | 42.2 |
| 2024 | 44.3 |
| 2025 | 74.3 |
Opportunities · 0712.5% of this theme group
Focuses on circulating tumor cell analysis and molecular markers guiding individualized oncology strategies.
Cancer (241) · Precision medicine (207) · Breast cancer (90) · Lung cancer (44)
Bioinformatics-Based Analysis of Circulating Tumor Cells: A Methodological Overview of Personalized Cancer Treatment
[Molecular biomarkers in breast cancer : advances in precision medicine].
| Year | Share index |
|---|---|
| 2022 | 776.6 |
| 2023 | 1055.1 |
| 2024 | 810.2 |
| 2025 | 787.3 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 29.7% | 36.9% |
| Problem-identifying | 29.0% | 10.1% |
| Descriptive | 18.8% | 17.6% |
| Breakthrough | 12.7% | 26.3% |
| Cautionary | 6.4% | 4.4% |
| Comparative | 2.5% | 3.8% |
| Critical | 0.9% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 4,573 | 2.66% | 2,251 (49.2%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 292 | 0.17% | 167 (57.2%) | 0.17% |
| Bias & fairnessChallenges and recommendations for wearable devices in digital health: Data quality, interoperability, health equity, fa | 99 | 0.06% | 45 (45.5%) | 0.06% |
| Hardware, e-waste & supply chainE-waste for health: recycling smartphones for health monitoring | 24 | 0.01% | 7 (29.2%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 16 | 0.01% | 7 (43.8%) | 0.01% |
| Labour & data workNew Work—New Interventions: Digital Occupational Health Interventions and the Co-Creation of a Human-Centered Future of | 11 | 0.01% | 6 (54.5%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 10 | 0.01% | 4 (40.0%) | 0.01% |
| Carbon & emissions of computeSustainable AI-Enabled UAV Healthcare Logistics: Environmental, Social, and Governance Implications from a PRISMA-ScR Re | 3 | 0.0% | 1 (33.3%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Company counts, hiring and disclosed funding across the recorded hubs.
39.6% across the displayed hubs
7 companies hiring · $1.6B disclosed funding
Explore companies in Tel Aviv ↗
14.1% across the displayed hubs
0 companies hiring · $718.1M disclosed funding
Explore companies in Haifa ↗
12.5% across the displayed hubs
3 companies hiring · $591.5M disclosed funding
Explore companies in Jerusalem ↗
7.7% across the displayed hubs
2 companies hiring · $422.6M disclosed funding
Explore companies in Herzliya ↗
6.9% across the displayed hubs
5 companies hiring · $291.3M disclosed funding
Explore companies in Netanya ↗
6.9% across the displayed hubs
3 companies hiring · $393.1M disclosed funding
Explore companies in Rehovot ↗6.2% across the displayed hubs
1 companies hiring · $294.4M disclosed funding
Explore companies in Petah Tikva ↗
6.1% across the displayed hubs
1 companies hiring · $715.4M disclosed funding
Explore companies in Caesarea ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗